91245-59-9

Basic information

• Product Name: (1-PHENYLCYCLOBUTYL)METHYLAMINE
• Synonyms: 1-Phenyl-cyclobutaneMethylaMine;CyclobutaneMethanaMine,1-phenyl-;1-Phenyl-cyclobutanemethanamine
• CAS NO: 91245-59-9
• Molecular Formula: C₁₁H₁₅N
• Molecular Weight: 161.25
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het
• Mol File: 91245-59-9.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 256.7°Cat760mmHg
• Flash Point: 107.7°C
• Appearance: /
• Density: 1.018g/cm³
• Vapor Pressure: 0.015mmHg at 25°C
• Refractive Index: 1.558
• PKA: 10.27±0.29(Predicted)
• CAS DataBase Reference: (1-PHENYLCYCLOBUTYL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-PHENYLCYCLOBUTYL)METHYLAMINE(91245-59-9)
• EPA Substance Registry System: (1-PHENYLCYCLOBUTYL)METHYLAMINE(91245-59-9)

Safety Data

• Hazardous Substances Data: 91245-59-9(Hazardous Substances Data)

Usage

General Description

(1-Phenylcyclobutyl)methylamine is a chemical compound with the molecular formula C11H15N. It is an amine derivative with a cyclobutyl ring and a phenyl group attached to the nitrogen atom. (1-PHENYLCYCLOBUTYL)METHYLAMINE is used in organic synthesis and medicinal chemistry as a building block for the preparation of various biologically active molecules and pharmaceuticals. It may also have potential applications in the development of new drugs and materials due to its unique chemical structure. Additionally, it is important to handle this compound with care and to follow proper safety protocols when working with it in a laboratory setting.

InChI:InChI=1/C11H15N/c12-9-11(7-4-8-11)10-5-2-1-3-6-10/h1-3,5-6H,4,7-9,12H2

Upstream product

• 14377-68-5 1-phenylcyclobutanecarbonitrile 

Downstream Products

• 850875-62-6 4,4-siprocyclobutyl-1,2,3,4-tetrahydro-isoquinoline 
• 850875-63-7 (1-Phenyl-cyclobutylmethyl)-carbamic acid methyl ester 
• 551943-96-5 (4β,5α)-12-Hydroxy-N-[(1-phenylcyclobutyl)methyl]podocarpa-8,11,13-trien-16-amide 

Relevant articles and documents

MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION

The present invention provides compounds of the general formulas I-IX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The present invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Pyrazinone protease inhibitors

Pyrazinone compounds are described, including compounds of the Formula I: wherein X is O, NR11or CH═N, R3-R11, Ra, Rb, Rc, W, m, and n are set forth in the specification, as well as hydrate

Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 4. A Novel Series of Urea ACAT Inhibitors as Potential Hypocholesterolemic Agents

We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT).This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia.For this series of compounds, the in vitro ACAT inhibitory activity was improved by increasing the bulk of the 2,6-substituents on the phenyl ring.Additionally, we found that spacing of the aromatic rings was critical for ACAT inhibitory activity.A phenyl ring five atoms away from the requiste 2,6-diisopropylphenyl moiety was optimal for in vitro activity.Substitution α to the N'-phenyl moiety enhanced in vitro potency.In the case of phenylcycloalkyl ureas, ACAT inhibitory activity was independent of the size of the cycloalkyl ring.From this series of analogs, compound 25, which had excellent in vitro potency for inhibiting ACAT, was found to lower plasma cholesterol by 73percent in vivo when administrated in the diet at 50 mg/kg in an animal model of hypercholesterolemia.In this model, compound 25 lowered plasma cholesterol dose dependently and was as efficacious as the Lederle ACAT inhibitor CL 277082.